With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine
J&J researchers rolled out data from the first two pivotal trials of their anti-depression drug esketamine today, blazing a trail that they say leads straight …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
